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A B S T R A C T
The transient potential vanilloid 1 receptor (TRPV1) is a calcium-permeable channel responsible for the
transduction and modulation of acute and chronic pain signaling. As such, this receptor is a potential
target for the treatment of a number of pain disorders. However, AMG517, a TRPV1 antagonist, presents
several clinical limitations that include the induction of severe hyperthermia. The aim of this study was
to investigate the possible interaction of the ﬂavonoid eriodictyol with the TRPV1 receptor and to
determine its putative antinociceptive and hyperthermic effects. Eriodictyol was able to displace [3H]-
resiniferatoxin binding (IC50 = 47; 21–119 nM) and to inhibit calcium inﬂux mediated by capsaicin
(IC50 = 44; 16–125 nM), suggesting that eriodictyol acts as a TRPV1 antagonist. Moreover, eriodictyol
induced antinociception in the intraplantar capsaicin test, with maximal inhibition of 49  10 and
64  4% for oral (ID50 = 2.3; 1.1–5.7 mg/kg) and intrathecal (ID50 = 2.2; 1.7–2.9 nmol/site) administration,
respectively. Eriodictyol did not induce any change in body temperature or locomotor activity. Orally
administered eriodictyol (4.5 mg/kg) prevented the nociception induced by intrathecal injections of
capsaicin, as well as the non-protein thiol loss and 3-nitrotyrosine (3-NT) formation induced by capsaicin in
spinal cord. Eriodictyol also reduced the thermal hyperalgesia andmechanical allodynia elicited by complete
Freund’s adjuvant (CFA) paw injection. In conclusion, eriodictyol acts as an antagonist of the TRPV1 receptor
and as an antioxidant; it induces antinociception without some of the side effects and limitations such as
hyperthermia that are expected for TRPV1 antagonists.
 2010 Elsevier Inc.
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Transient receptor potential (TRP) channels represent a
superfamily of six-transmembrane-domain ion channels that are
permeable to cations, primarily calcium [1]. TRPV1 is a member of
the vanilloid TRP subfamily and is activated by harmful stimuli
such as heat and acidiﬁcation as well as by chemical irritants such
as capsaicin. The TRPV1 receptor is activated by several endoge-
nous substances, including anandamide and leukotriene B4, and
has been implicated in the development of certain inﬂammatory
diseases and neuropathic pain [2,3].
It has been demonstrated that antagonism of TRPV1 leads to
antinociception in several models of inﬂammatory and neuro-* Corresponding author at: Departamento de Quı´mica, Universidade Federal de
Santa Maria, Avenida Roraima 1000, Camobi, CEP 97105-900, Santa Maria, RS,
Brazil. Tel.: +55 55 3220 8053; fax: +55 55 3220 8031.
E-mail address: ferreiraj99@gmail.com (J. Ferreira).
0006-2952  2010 Elsevier Inc.
doi:10.1016/j.bcp.2010.11.004
Open access under the Elsevier OA license.pathic pain [4,5]. Moreover, the genetic ablation of TRPV1
receptors has also been used to demonstrate its importance in
pain transmission [6–8]. However, a recent clinical trial of
AMG517, a TRPV1 antagonist, showed this compound to be
unsatisfactory for pain treatment due to some severe side effects,
primarily the development of hyperthermia [9]. Thus, a search for
novel compounds that modulate TRPV1 channel activity and have
safe and efﬁcient analgesic effects is necessary.
To address this question, our research group has been examining
several natural compounds that are structurally similar to known
TRPV1 ligands. In these tests, we selected the ﬂavonoid eriodictyol
(30,40,5,7-tetrahydroxyﬂavanone), which presents some character-
istics commonly found in TRPV1 ligands (Fig. 1), such as regions A
and B that are present in capsaicin, a TRPV1 agonist [10,11].
Furthermore, eriodictyol also shows antioxidant effects [12], and
somestudieshave indicated that antioxidant compounds, suchasN-
acetylcysteine (NAC), induce antinociception in several painmodels
[13,14]. These ﬁndings suggest that eriodictyol has the potential to
exert antinociceptive action.
[(Fig._1)TD$FIG]
Fig. 1. Chemical structures of the TRPV1 receptor ligands (A) capsaicin and (B) the
ﬂavonoid eriodictyol (30 ,40 ,5,7-tetrahydroxyﬂavanone).
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interaction of eriodictyol with the TRPV1 receptor and to evaluate
its possible antinociceptive effect.
2. Materials and methods
2.1. Animals
Three-month-old male albino Swiss mice (25–35 g) and male
Wistar rats (200–300 g) bred in our animal house were used in this
study. Animals were housed at a controlled temperature
(22  2 8C) with a 12 h light/dark cycle and were provided standard
lab chowand tapwater ad libitum. The animalswere habituated to the
experimental room for at least 1 h before experiments. Each animal
was used for only one experiment. The experiments reported in this
study were carried out in accordance with current ethical guidelines
for the investigation of experimental pain in conscious animals [15]
andwere approved by the Ethics Committee of the Federal University
of Santa Maria (process number 23081.001086/2009-87).
2.2. Drug treatments
To determine the possible systemic antinociceptive effect of
eriodictyol, eriodictyol dissolved in 5% Tween 80, 20% polyethyl-
ene glycol and 75% saline (0.9% NaCl) was orally administered to
the animals. For intrathecal treatment, the eriodictyol stock
solution was dissolved in the same vehicle and diluted in
phosphate-buffered saline (PBS, composition in mmol/L: 137
NaCl, 2.7 KCl and 10 phosphate buffer) to the desired concentra-
tion (ﬁnal concentration: 0.05% Tween 80 and 0.2% polyethylene
glycol). The intrathecal injection of vehicle alone had no effect.
The TRPV1 antagonists AMG9810 and SB366791 [16,17] were
dissolved in the same vehicle and administered orally. For in vitro
assays, stock solutions of all compoundswere dissolved in ethanol
and diluted in PBS. The ﬁnal concentration of ethanol was not
higher than 0.1%.
The procedure for intrathecal (i.t.) administration was based on
a previously described technique [18]. Brieﬂy, the intervertebral
space between L5 and L6 was punctured directly using a 28-gauge
needle attached to a Hamilton micro syringe. A total volume of
5mL was administered. Mice were not anesthetized during these
procedures. A tail ﬂick was used as an indication that the needle
had penetrated the dura.
2.3. [3H]-Resiniferatoxin binding assay
Because eriodictyol is structurally similar to some known
TRPV1 ligands, we investigated the possibility that it binds to the
TRPV1 receptor. We tested eriodictyol using the [3H]-resinifer-atoxin ([3H]-RTX) binding assay as described previously [19].
Brieﬂy, spinal cord tissue was homogenized in buffer A (pH 7.4,
5 mM KCl, 5.8 mM NaCl, 2 mM MgCl2, 0.75 mM CaCl2, 137 mM
sucrose, and 10 mM HEPES) and centrifuged for 10 min at
1000  g at 4 8C. The supernatant was then centrifuged for
30 min at 35,000  g at 4 8C. The resulting pellets were
resuspended in buffer A and frozen until the day of assay. The
binding mixture (ﬁnal volume 500 mL) contained buffer A plus
0.25 mg/mL bovine serum albumin (BSA), membranes (0.5 mg/
mL), and 2 nM [3H]-RTX in the presence or absence of eriodictyol
(3–300 nM). For themeasurement of nonspeciﬁc binding, 100 mM
non-radioactive RTX was used. The reaction was initiated by
incubating tubes at 37 8C for 60 min and was stopped by
transferring the tubes to an ice bath and adding 100 mg of bovine
a1-acid glycoprotein to reduce non-speciﬁc binding. Free [
3H]-
RTX was separated frommembrane-bound [3H]-RTX by centrifu-
gation for 30 min at 35,000  g at 4 8C. Scintillation counting was
used to quantify binding. Speciﬁc binding, which represented 60–
70% of the total binding, was calculated as the difference between
total and non-speciﬁc binding. The results are reported as % of
speciﬁc binding.
2.4. Calcium inﬂux assay
After evaluating the ability of eriodictyol to bind to the TRPV1
receptor, we measured its capacity to change calcium inﬂux.
Synaptosomes were prepared from rat spinal cord samples and
incubated with Fura 2-AM (10mM) for 30 min at 37 8C. The
reaction was diluted to 1.5 mL (5 mg/mL of protein) with Krebs-
Ringer medium (Ca2+ free) and incubated for 30 min at 37 8C. The
reaction was stopped by centrifugation (30 s at 12,000  g), and
the ﬁnal pellet was resuspended in 1.5 mL Krebs-Ringer medium
(Ca2+ free). To start the reaction, 1.5 mL of 1 M CaCl2 (1 mM) plus
different concentrations of eriodictyol were added followed by the
addition of capsaicin (20 mM). We measured Ca2+ inﬂux by
monitoring ﬂuorescence at 505 nm from excitation at 382 nm in a
spectroﬂuorimeter (RF-5301 PC, Shimadzu). Background ﬂuores-
cence from an equivalent sample of synaptosomes not loaded with
fura 2-AMwas recorded at the beginning of the experiment. At the
end of each experiment, calibration was performed by recording
maximum ﬂuorescence values after the addition of 15mL of 10%
Triton X100. Results are expressed as percentage of the maximum
response obtained with Triton [20].
2.5. Capsaicin-induced nociception
The peripheral capsaicin test was carried out as previously
described [21,22]. Animals were habituated to the observation
location, which consisted of a glass chamber, for at least 30 min
before the experiment. Following habituation, 20 mL of capsaicin
(1 nmol/paw) was injected intraplantarly (i.pl) into the right hind
paw, and the total time spent licking and ﬂinching the injected paw
was measured for 5 min as a nociception index. For the spinal
capsaicin test, 0.2 nmol/site of capsaicin was injected i.t. as
previously described [22]. In this test, the total time spent licking
the hind paws and tail during the 5 min following injection was
used as a measure of nociception. The vehicle used in each test
(0.15% ethanol in saline for i.pl. test and PBS for the i.t. test) was
prepared and used as a control treatment; it did not evoke
nociceptive behavior (data not shown).
2.6. CFA-induced inﬂammation
To induce the development of inﬂammatory thermal hyper-
algesia and mechanical allodynia, we used the CFA-induced
inﬂammatory pain model. Animals were anesthetized with
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Mycobacterium tuberculosis in liquid parafﬁn) was injected into the
right hind paw. Forty-eight hours later, the nociceptive alterations
were observed [22,23].
2.7. Thermal hyperalgesia measurement
Thermal hyperalgesia was recorded using previously described
methods [24] with minor modiﬁcations. Brieﬂy, animals were
habituated in a Plexiglas chamber for 30 min; a radiant light beam
generated by a 60W light bulb was then directed onto the right
hind paw (Plantar test, Ugo Basile, Italy). The time between the
onset of the stimulus and manifestation of the paw withdrawal
response was automatically measured and taken as an index of the
thermal nociceptive threshold.
2.8. Mechanical allodynia measurement
Mechanical allodynia was evaluated with the up-and-down
method [25] using von Frey ﬁlaments. Brieﬂy, mice were placed in
cages with a wire mesh bottom that allowed full access to the
paws. The paw was touched with a series of 7 von Frey hairs with
logarithmic increments (0.02, 0.07, 0.16, 0.4, 1.4, 4.0 and 10.0 g).
The von Frey hairs were applied perpendicular to the plantar
surface with sufﬁcient force to cause slight buckling against the
paw and held for approximately 2–4 s. Stimuli were presented at
intervals of several seconds, allowing for the resolution of any
behavioral responses to previous stimuli.
2.9. Locomotor activity
To evaluate possible non-speciﬁc muscle relaxant or sedative
effects of the administered compound, mice were subjected to
motor impairment evaluation [26]. We ﬁrst examined spontane-
ous motor coordination in the open-ﬁeld test. The apparatus
consisted of a Plexiglas boxmeasuring 40 cm  60 cm  50 cm, the
ﬂoor of which was divided into 12 equal squares. The number of
squares crossed with all paws, as well as the animal’s hearing
behavior, was measured in a 5-min session. Forced motor activity
was also evaluated using the rota-rod test. Twenty-four hours
before the experiment, all animals were trained on the rota-rod
(3.7 cm in diameter; 8 r.p.m.) until they could remain on the
apparatus for 60 s without falling. On the day of the experiment,
animals were subjected to the rota-rod test 1 h after the
administration of eriodictyol (4.5 mg/kg, p.o.) or vehicle (10 ml/
kg, p.o.). The total number of falls that occurred over a 240 s period
and the latency for the ﬁrst fall from the apparatus was recorded.
2.10. Body temperature
Because some TRPV1 ligands and antioxidants may modulate
body temperature, we investigated the effect of eriodictyol on body
temperature. The animals’ rectal temperaturewas determined; they
were then given vehicle, eriodictyol (4.5 mg/kg), SB366791 (10 mg/
kg) or AMG9810 (10 mg/kg) orally. New temperature measure-
ments were taken at various time points following drug adminis-
tration, and the difference (D8C) between pre-injection and post-
injection values was calculated as previously described [27].
2.11. Antioxidant activity
2.11.1. ABTS assay
To determine whether eriodictyol has antioxidant activity, we
performed the ABTS radical reduction test [28,29]. Brieﬂy, 1 mL of
ABTS solution (7 mM) was incubated in the dark with potassium
persulfate (140 mM) for 16–18 h at room temperature. Thesolution was then diluted (1:88) in phosphate buffer (10 mM,
pH 7.0). To perform the reaction, 1 mL of diluted ABTS solutionwas
incubated with 0.1 mL of sample for 30 min in the dark. Rutin was
used as a positive control, and water was used as a blank (100% of
absorbance).
2.11.2. Estimations of thiol levels
Following nociception testing, animals were sacriﬁced using
halothane, and the lumbar portion of the spinal cord was collected
for the estimation of non-protein thiol content [30]. Tissue was
homogenized in 1.0 mL of 0.02 M EDTA and the homogenate was
centrifuged at 4000  g for 15 min at 4 8C. The supernatant
(300 mL) was incubated with 50 mL of 50% TCA at 4 8C for 60 min
and then centrifuged at 12,000  g for 5 min at 4 8C; the resulting
supernatant was used for determination of the non-protein thiol
content of the sample. For this, 200mL of Tris/HCl (200 mM, pH
8.9) and 20 mL of DTNB (2.5 mM) were added to a 100-mL sample
in a microplate and incubated at room temperature for 5 min. The
resulting color was measured at 405 nm using a FisherBiotech
Microkinetics Reader BT 2000. Cysteine was used as a standard to
determine the thiol (SH) content in the samples, and thiol levels
were corrected for its protein contents. Protein was measured
using Coomassie Blue dye with BSA as a standard [31].
2.11.3. Slot-blot assay for 3-nitrotyrosine
Peroxinitrite is one of themost reactive nitrogen species formed
during oxidative stress; it can attack proteins, leading to the
production of 3-nitrotyrosine (3-NT) and altered functioning. Thus,
we measured the level of 3-NT in lumbar spinal cord samples after
injection of capsaicin or vehicle and used it as a marker of reactive
species production [22]. Brieﬂy, 5mL of sample was added to 5 mL
of 12% SDS and 5mL of Laemmli buffer (pH 6.8; 0.125 MTris, 4% SDS
and 20% glycerol) and incubated for 20 min at room temperature.
The resulting solution was applied to a nitrocellulose membrane
under vacuum using a slot-blot apparatus. The membrane was
blocked in blocking buffer (3% BSA) for 1 h and incubated for 1 h
with an anti-3-NT polyclonal antibody diluted 1:2000 in PBS
(0.05 mM, pH 7.4) containing 0.01% sodium azide and 0.2% Tween
20. The membrane was washed three times in PBS and incubated
for 1 h with an alkaline phosphatase-conjugated anti-rabbit IgG
secondary antibody diluted in PBS (1:8000). Blots were dried,
scanned using Adobe Photoshop, and quantiﬁed using Scion Image
(PC version of Macintosh-compatible NIH image). The 3-NT blot
displayed a faint background that was corrected for in image
analysis.
2.12. Drugs and reagents
Eriodictyol was either isolated from the ethyl acetate fraction
obtained from the leaves of Vernonia tweedieana Baker by column
chromatography on silica gel or purchased from Sigma (St. Louis,
USA). The structure was identiﬁed by spectroscopic methods,
primarily 1H NMR, 13C NMR and Dept 135 spectra, and by
comparison with published data. Eriodictyol purity (>95%) was
veriﬁed by HPLC–DAD. No difference in biological effect or purity
was observed in the eriodictyol from the two sources in in vitro and
in vivo experiments. Capsaicin, sodium dodecyl sulfate (SDS),
glycerol, polyethylene glycol 400, PBS, bovine serum albumin
(BSA), Tween 20, Tween 80, anti-rabbit IgG alkaline phosphatase
secondary antibody, anti-3-NT polyclonal antibody, a1-acid
glycoprotein, DTNB (5,50-dithiobis(2-nitro-benzoic acid)), CFA,
SB366791, AMG9810, 2,20-azino-bis(3-ethylbenzthiazoline-6-sul-
fonic acid) diammonium salt (ABTS), potassium persulfate, rutin
and Fura 2-AM (stock solution 1 mM in dimethyl sulfoxide, DMSO)
were purchased from Sigma (St. Louis, USA). Trichloroacetic acid
(TCA) and cysteine were purchased from Vetec (Rio de Janeiro,
[(Fig._2)TD$FIG]
Fig. 2. Effects of eriodictyol on the TRPV1 receptor. Capacity of eriodictyol to (A)
bind to the TRPV1 receptor and displace [3H]-RTX binding and (B) to inhibit the
calcium inﬂux elicited by capsaicin (20 mM). Each point represents the mean of the
speciﬁc binding (%, A) or the change in [Ca2+]i (%, B)  SEM of four experiments
conducted in duplicate.
Table 1
Side effects evaluated 1h after vehicle or eriodictyol (4.5mg/kg, p.o.) administra-
tion.
Treatment (p.o.) Rota-rod Open ﬁeld
First fall (s) Falls Crossing Rearing
Vehicle 93.212.0 2.30.8 50.87.2 13.61.9
Eriodictyol 64.632.2 1.30.9 33.56.6 8.52.6
No signiﬁcant differences were observed between groups, Student’s t test. Results
are expressed as the mean S.E.M (n =5).
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from PerkinElmer (Boston, USA) and diluted in buffer A before use.
2.13. Statistical analysis
The results are presented as mean  S.E.M. except in the case of
ID50 (the dose of compound that inhibits the nociceptive effect by 50%
relative to the control value) and IC50 (the concentration of compound
that inhibited calcium inﬂux or binding by 50% relative to the control
value) values, which are reported as geometric means accompanied
by respective 95% conﬁdence limits. The ID50 and IC50 values were
determined by non-linear regression analysis with a sigmoid dose-
response equation using GraphPad Software 5.0 (Graph Pad, USA).
The percentages of maximal inhibition (Imax) are reported as the
mean  S.E.M. of the inhibition obtained in each individual experi-
ment in relation to the control values (vehicle for the in vivo results;
100% of speciﬁc binding for the [3H]-RTX binding assay; 100% of
maximumresponse obtainedwith triton for the calcium inﬂux assay).
The level of signiﬁcancewas set at p < 0.05. Datawere analyzed using
Student’s t-test, one-way analysis of variance (ANOVA) followed by
Student–Newman–Keuls’s (SNK) post-hoc test or two-way ANOVA
followed by Bonferroni’s post-hoc test.
3. Results
3.1. Characterization of TRPV1 antagonism
3.1.1. [3H]-Resiniferatoxin binding
Initially, we determined the possible interaction of eriodictyol
with the TRPV1 receptor. A binding assay was performed using
[3H]-RTX, which is a ligand of the vanilloid site of the TRPV1
receptor. Eriodictyol was able to displace [3H]-RTX-speciﬁc
binding from rat spinal cord membranes with an IC50 of 47 (21–
119) nM and an Imax of 68.9  9.0% (Fig. 2A).
3.1.2. Effects of eriodictyol on intrasynaptosomal calcium inﬂux
To determine the functional effects of eriodictyol binding, we
investigated its capacity to alter calcium inﬂux mediated by
capsaicin. In this study, eriodictyol inhibited the calcium inﬂux
elicited by capsaicin in spinal cord synaptosomes with an IC50 of
44 nM (Fig. 2B). Eriodictyol (300 nM) in the absence of capsaicin
did not alter the calcium inﬂux (results not shown).
3.2. Characterization of eriodictyol effects in vivo
3.2.1. Antinociceptive effect of eriodictyol
We investigated the possible antinociceptive effect of eriodic-
tyol using a capsaicin-induced overt nociception test. In mice,
orally administered eriodictyol had an antinociceptive effect with
an ID50 of 2.3 (1.1–5.7) mg/kg and an Imax of 49  10%. The
eriodictyol-induced antinociceptive effect (4.5 mg/kg, p.o.) started
1 h after treatment and lasted for up to 2 h (Fig. 3A and B).
Eriodictyol was also administered intrathecally (1–10 nmol/
site). With this route of administration, we observed a greater
antinociceptive effect that began 15 min and lasted until 4 h after
administration and that displayed an ID50 of 2.2 (1.7–2.9) nmol/
site and an Imax of 64  4% (Fig. 3C and D). We then performed the
intrathecal capsaicin test and administered eriodictyol orally (4.5 mg/
kg) to determinewhether oral eriodictyol was able to reach the spinal
cord and inhibit central noxious stimulation. In this protocol, a
71  5% inhibition of nociception was observed (Fig. 3E).
We did not observe any change in locomotor activity after
eriodictyol administration in either the rota-rod or open-ﬁeld
tests. Thus, the antinociceptive effect of eriodictyol is not due to
any alteration in motor performance (Table 1).3.2.2. CFA-induced nociception
Because the TRPV1 receptor may be activated during the
inﬂammatory process at the site of inﬂammation and in the spinal
cord, we evaluated the effect of eriodictyol and SB366791 or
AMG9810, which were used as positive controls for the effects of
compounds that antagonize TRPV1 receptor activation, on the
thermal hyperalgesia and mechanical allodynia induced by CFA.
Onehour after administration, eriodictyol (4.5 mg/kg, p.o.) caused
an anti-hyperalgesic and anti-allodynic effect, fully reversing
hyperalgesia (100%) and partially reducing the allodynia
(64  7%). At the same time, AMG9810 (10 mg/kg, p.o.) reduced
only 92  3% of the hyperalgesia and 55  26% of the allodynia
induced by CFA, while SB366791 (10 mg/kg, p.o.) reduced only the
thermal hyperalgesia induced by CFA (89  10%) without altering
the mechanical allodynia (Fig. 4).
[(Fig._3)TD$FIG]
Fig. 3. Antinociceptive effect of eriodictyol measured in the capsaicin test. Dose-response effect of eriodictyol administered (A) orally or (C) intrathecally 1 h before the
intraplantar capsaicin test. The time course of eriodictyol administered orally (B; 4.5 mg/kg) or intrathecally (D; 10 nmol/site) in the intraplantar capsaicin test. (E) Effect of
eriodictyol (4.5 mg/kg, p.o.) on the nociception induced by intrathecal capsaicin (0.2 nmol/site). Data are expressed as the mean  SEM (n = 6–7) of the nociception time (s).
*p < 0.05, **p < 0.01, based on Student’s t-test (E), one-way ANOVA followed by SNK post-hoc test (A and C) or two-way ANOVA followed by Bonferroni’s post-hoc test (B and D).
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The development of marked hyperthermia is a major limitation
in the use of TRPV1 antagonists in clinical trials. We therefore
assessed the effect of eriodictyol (4.5 mg/kg, p.o.), SB366791
(10 mg/kg, p.o.) and AMG9810 (10 mg/kg, p.o.) on rectal tempera-
ture inmice. Neither eriodictyol nor SB366791 signiﬁcantly altered
basal temperature, while AMG9810 induced a 2.48  0.15%
increase in the rectal temperature (Fig. 5).
3.3. Antioxidant activity
It is known that TRPV1 activation not only elicits nociception
but also causes oxidative stress, which seems to contribute tocentral pain signaling [22]. Use of the intraplantar capsaicin test
demonstrated a decrease in non-protein thiol levels 5 min after
capsaicin injection into the lumbar spinal cord, and pretreatment
with eriodictyol (4.5 mg/kg) prevented this loss (Fig. 6A).
Another event associated with peripheral noxious stimulation
is an increase in the rate of formation of peroxynitrite; this
compound attacks tyrosine residues leading to the formation of
3-nitrotyrosine (3-NT) [32]. We measured 3-NT levels in the
lumbar spinal cords of mice treated with vehicle or with
eriodictyol (4.5 mg/kg, p.o.). As previously described [22], an
increase in 3-NT levels in the lumbar spinal cord was seen 5 min
after intraplantar capsaicin injection and this increase was
prevented by pretreatment with eriodictyol. Eriodictyol did not
[(Fig._4)TD$FIG]
Fig. 4. Effect of eriodictyol (4.5 mg/kg, p.o.), SB366791 (10 mg/kg, p.o.) and
AMG9810 (10 mg/kg, p.o.) on the nociception induced by complete Freund’s
adjuvant (CFA). Effect of the treatments on (A) hyperalgesia and (B) allodynia
elicited by intraplantar CFA. Data are expressed as the mean  SEM of the latency (s,
A) or themechanical threshold 50% (g, B). *p < 0.05, comparedwith vehicle group, two-
way ANOVA followed by Bonferroni’s post-hoc test (n = 6–7).
[(Fig._5)TD$FIG]
Fig. 5. Body temperature measured after treatment with eriodictyol (4.5 mg/kg,
p.o.), SB-366971 (10 mg/kg, p.o.) or AMG9810 (10 mg/kg, p.o.). Data are expressed
as the mean  SEM of the change in body temperature (D8C) in comparison to the
basal level. *p < 0.05 compared with vehicle pretreated mice, two-way ANOVA
followed by Bonferroni’s post-hoc test (n = 6).
[(Fig._6)TD$FIG]
Fig. 6. Levels of oxidative stress markers measured in a lumbar spinal cord sample
5 min after intraplantar injection of capsaicin (1 nmol/paw). Non-protein thiol
content (SH; A) or 3-nitrotyrosine (3-NT; B) after eriodictyol (4.5 mg/kg, p.o.)
treatment (n = 4–6). (C) Antioxidant effect of eriodictyol or rutin in the ABTS
scavenger assay. Data are expressed as the mean  SEM of the SH and 3-NT levels (A
and B, n = 6–7) or the mean  SEM of the % inhibition of ABTS oxidation (C, 3
experiments carried out in duplicate). *p < 0.05 compared with vehicle pretreated
mice (black bars), one-way ANOVA followed by SNK post-hoc test. Non-protein thiol
levels are represented as free SH levels and 3-NT levels as % of control (vehicle–vehicle)
treated group.
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vehicle injections (Fig. 6B).
The prevention of the oxidative stress that normally occurs
following intraplantar capsaicin injection may result in part from
the ability of eriodictyol to antagonize the TRPV1 receptor and in
part from an associated antioxidant activity. To evaluate this
possibility, we performed the ABTS radical test used to screen
M.F. Rossato et al. / Biochemical Pharmacology 81 (2011) 544–551550antioxidant compounds. In this experiment, eriodictyol showed
antioxidant activity similar to that of rutin (positive control) with
an IC50 of 1.7 (1.3–2.1)mM (Fig. 6C).
4. Discussion
The transient receptor potential (TRP) family represents a
superfamily of ion channels formed by six transmembrane
domains that are capable of permeating cations, primarily calcium.
These channels, particularly the subtype vanilloid 1 (TRPV1), are
involved in the detection and transmission of painful stimuli [1]. As
a result, these receptors have been implicated as a possible target
for pain treatment [33]. To ﬁnd new molecules that interact with
this receptor, we tested the ﬂavonoid eriodictyol. This compound
inhibited the binding of a knownmodulator to the TRPV1 receptor
and inhibited the calcium inﬂuxmediated by capsaicin. Eriodictyol
also had an antinociceptive effect in the intraplantar and
intrathecal capsaicin tests and antihyperalgesic and anti-allodynic
effects in the CFA test. Furthermore, we observed that eriodictyol
fully prevented the oxidative stress induced by capsaicin in the
spinal cord without altering motor activity or body temperature.
To begin the search for new molecules that may interact with
the TRPV1 receptor, we focused on compounds found in medicinal
plants with known antinociceptive effects. We tested several
compounds in the [3H]-RTX binding assay to determine which
compounds could interact with the vanilloid site of TRPV1. Based
on preliminary ﬁndings, we selected the ﬂavonoid eriodictyol,
which displaces [3H]-RTX binding with greater potency (approxi-
mately 47 nM) than the classical TRPV1 agonist capsaicin
(approximately 3200 nM) [34]. We then used a capsaicin-mediat-
ed calcium inﬂux assay to determine whether eriodictyol binding
leads to functional modulation of the TRPV1 receptor. Eriodictyol
inhibited calcium inﬂux with potency similar to that observed in
the binding assay and had no effect on calcium inﬂux in the
absence of capsaicin. This indicates that eriodictyol acts as an
antagonist of the TRPV1 receptor and that it inhibits calcium inﬂux
with greater potency than some classical TRPV1 antagonists,
including SB366791 (651.9 nM, [35]), 5-iodoresineferatoxin
(56.7 nM, [36]) and capsazepine (7.7 mM, [37]).
TheTRPV1 receptor is currently themost promising target for the
development of new analgesic drugs [38]. The vanilloid receptor is
distributedboth in theperiphery,where it acts as a sensor ofnoxious
stimuli, and in the spinal cord, where it participates in the
transmission of pain [39]. After determining that eriodictyol acts
as an antagonist of the TRPV1 receptor in vitro, our next step was to
determine whether it could attenuate the nociception induced by
capsaicin. Eriodictyol had antinociceptive effects with high efﬁcacy
and potency when administered either orally or intrathecally.
Furthermore, oral eriodictyol administration attenuated the noci-
ception induced by intrathecal capsaicin, suggesting that orally
administered eriodictyol may reach the spinal cord. This is a critical
feature for new drug development, because most compounds used
to treat pain are administered orally [40].
Despite the fact that the capsaicin pain model is useful for
screening antinociceptive compounds that may act on the TRPV1
receptor, it does not have a good correlationwith clinical pain [41].
We therefore tested the effects of eriodictyol, SB366791 and
AMG9810 on CFA-induced arthritis. Eriodictyol and AMG9810 had
both anti-allodynic and anti-hyperalgesic effects, while SB366791
showed only an anti-hyperalgesic effect. In several disease
processes, TRPV1 receptor levels may also be modulated, resulting
in increased sensitivity to pain. In rodents, an increase in the
expression of TRPV1 protein at the site of the chronic inﬂammation
induced by CFA has been observed, and it has been shown that this
leads to increased sensitivity to thermal stimulation [42]. Similar
increases in TRPV1 expression have also been reported in humanswith local inﬂammation [43]. In chronic painful processes,
increases in TRPV1 function mediated by post-transcriptional
events such as phosphorylation and nitration at distinct sites of the
TRPV1 receptor have been observed [44,45]. These facts clearly
indicate a critical role for this receptor in the ontogeny of pain. The
observation that eriodictyol effectively reversed the nociception
caused by CFA has potential clinical implications for this
compound in light of the fact that patients are usually treated
for well-established painful conditions.
Although hyperthermia is a common side effect of TRPV1
antagonists, we found that eriodictyol had no effect on body
temperature, while AMG9810 induced hyperthermia in mice.
Administration of AMG517, an analog of AMG9810, was recently
shown to cause marked and persistent hyperthermia (approxi-
mately 40 8C) in humans at doses smaller than those necessary to
elicit an analgesic effect. The hyperthermia elicited by AMG517 has
been found to be resistant to classical treatments for fever, such as
acetaminophen. This hyperthermia was attributed to an increase
in peripheral vasoconstriction, which decreases heat loss through
the skin, increasing the body temperature [9]. Eriodictyol has been
shown to cause vasorelaxation [46]; this could explain why
eriodictyol did not induce hyperthermia. These data suggest that
eriodictyol may be a safer treatment than other currently known
TRPV1 antagonists.
Our research group recently demonstrated that capsaicin-
induced nociception occurs concomitantly with spinal oxidative
stress. Treatment with NAC, an ROS scavenger, attenuated both the
oxidative stress and the nociception induced by capsaicin. Thus,
ROs production appears to be an important mechanism of pain
induction/transmission in mice [22]. The TRPV1 receptor seems to
play a critical role in oxidative stress-mediated nociception. The
stimulation of TRPV1 receptors may induce oxidative stress in
sensory neurons and the spinal cord, and some oxidants may
modulate TRPV1 receptor function [22,44,47]. Here we found that
eriodictyol prevented the development of oxidative stress in the
lumbar spinal cord. This effect may be due either to direct
antagonism of the TRPV1 receptor or to an antioxidant effect. To
distinguish between these alternatives, we performed the ABTS
test and conﬁrmed that eriodictyol also has an antioxidant effect
[47]. Even though eriodictyol has an approximately 38-fold greater
potency for antagonism of the TRPV1 receptor than for antioxidant
activity, a direct antioxidant effect could contribute, at least in part,
to its antinociceptive effect.
The occurrence of oxidative stress has been described in several
animalmodels of pain, and oxidative stress has been implicated as a
mechanism in the induction and maintenance of pain [48]. This
hypothesis is strengthened by the fact that some antioxidant
substances present antinociceptive effects on both mechanical
allodynia and thermal hyperalgesia, as observed for eriodictyol
[22,48]. Somemolecular targets involved in nociception, such as the
NMDAreceptor and theexcitatoryaminoacid transporter1 (EAAT1),
have also been implicated in oxidative stress [31]. Thus, eriodictyol
could induce antinociception by directly antagonizing the TRPV1
receptor as well as by protecting other targets of reactive species.
In summary, the ﬂavonoid eriodictyol induced antinociceptive,
anti-allodynic and anti-hyperalgesic effects in mice without
altering locomotor activity or body temperature. The antinoci-
ceptive effects of eriodictyol seem to be due to a combination of
TRPV1 antagonism and an antioxidant effect. Thus, eriodictyolmay
be a good prototype for the development of more effective and/or
more potent agents for the treatment of pain.
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